This article is about testosterone as a medication. For the natural hormone, see Testosterone.TestosteroneClinical dataPronunciation teh-STOS-t-rohn Trade namesAndroGel, Testim, TestoGel, othersSynonymsAndrost-4-en-17-ol-3-oneAHFS/Drugs.comMonographMedlinePlusa614041License dataPregnancycategoryRoutes ofadministrationTransdermal (gel, cream, solution, patch), by mouth (as testosterone undecanoate), in the cheek, intranasal (gel), intramuscular injection (as esters), subcutaneous pelletsDrug classAndrogen, anabolic steroidATC codeLegal statusLegal statusPharmacokinetic dataBioavailabilityOral: very low (due to extensive first pass metabolism)Protein binding97.099.5% (to SHBG and albumin)MetabolismLiver (mainly reduction and conjugation)Elimination half-life24hoursExcretionUrine (90%), feces (6%)Identifiers
Testosterone is a medication and naturally occurring steroid hormone. It is used to treat male hypogonadism and certain types of breast cancer. It may also be used to increase athletic ability in the form of doping. It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. Testosterone can be used as a gel or patch that is applied to the skin, injection into a muscle, tablet that is placed in the cheek, or tablet that is taken by mouth.
Common side effects of testosterone include acne, swelling, and breast enlargement in men. Serious side effects may include liver toxicity, heart disease, and behavioral changes. Women and children who are exposed may develop masculinization. It is recommended that individuals with prostate cancer not use the medication. It can cause harm to the baby if used during pregnancy or breastfeeding. Testosterone is in the androgen family of medications.
Testosterone was first isolated in 1935. Rates of use have increased three times in the United States between 2001 and 2011. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The price depends on the dose and form of the product.
The primary use of testosterone is the treatment of males with too little or no natural testosterone production, also termed hypogonadism or hypoandrogenism (androgen deficiency). This treatment is referred to as hormone replacement therapy (HRT), or alternatively, and more specifically, as testosterone replacement therapy (TRT) or androgen replacement therapy (ART). It is used to maintain serum testosterone levels in the normal male range. Decline of testosterone production with age has led to interest in testosterone supplementation.
Testosterone deficiency (also termed hypotestosteronism or hypotestosteronemia) is an abnormally low testosterone production. It may occur because of testicular dysfunction (primary hypogonadism) or hypothalamicpituitary dysfunction (secondary hypogonadism) and may be congenital or acquired.
Testosterone levels may decline gradually with age. The United States Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone supplement have been established for low testosterone levels due to aging. The FDA has required that labels on testosterone include warnings about increased risk of heart attacks and stroke.
To take advantage of its virilizing effects, testosterone is administered to transgender men as part of masculinizing hormone therapy, titrated to clinical effect with a "target level" of the average male's testosterone level.
Testosterone therapy is effective in the short-term for the treatment of hypoactive sexual desire disorder (HSDD) in women. However, its long-term safety is unclear. Because of a lack data to support its efficacy and safety, the Endocrine Society recommends against the routine use of testosterone in women to treat low androgen levels due to hypopituitarism, adrenal insufficiency, surgical removal of the ovaries, high-dose corticosteroid therapy, or other causes. Similarly, because of a lack of data to support its efficacy and safety, the Endocrine Society recommends against the general use of testosterone in women to treat infertility; sexual dysfunction due to causes other than HSDD; to improve cognitive, cardiovascular, metabolic, and/or bone health; or to improve general well-being.
A 2014 systematic review and meta-analysis of 35studies consisting of over 5,000postmenopausal women with normal adrenal gland function found that testosterone therapy was associated with significant improvement in a variety of domains of sexual function. Such domains included frequency of sexual activity, orgasm, arousal, and sexual satisfaction among others. Women who were menopausal due to ovariectomy showed significantly greater improvement in sexual function with testosterone relative to those who had normal menopause. In addition to beneficial effects on sexual function, testosterone was associated with changes in blood lipids including decreased levels of total cholesterol, triglycerides, and high-density lipoprotein and increased levels of low-density lipoprotein. However, such changes were small in magnitude, and their long-term influence on cardiovascular outcomes is unclear. The changes were more pronounced with oral testosterone undecanoate compared to parenteral (e.g., transdermal) testosterone. Testosterone showed no significant effect on depressed mood or anxiety, anthropomorphic measures like body weight or body mass index, or bone mineral density. Conversely, it was associated with a significant incidence of androgenic side effects including acne and hirsutism, and other androgenic side effects like weight gain, pattern hair loss, and voice deepening were also reported in some trials but were excluded from the meta-analysis due to insufficient data. The overall quality of the evidence was rated as low and was considered to be inconclusive in certain areas, for instance long-term safety.
A subsequent 2017 systematic review and meta-analysis of over 3,000 postmenopausal women similarly found that transdermal testosterone therapy was effective in improving multiple domains of sexual function in the short-term treatment of HSDD. Androgenic adverse effects such as acne and hirsutism were significantly greater in incidence, while no significant differences in "increase in facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction to the patch, total adverse events, serious adverse events, reasons for withdrawal from the study, and the number of women who completed the study" were seen relative to the controls.
Although sufficient doses of testosterone are effective in improving sexual function in postmenopausal women, there is little support for the notion that testosterone is a critical hormone for sexual desire and function in women under normal physiological circumstances. Low doses of testosterone resulting in physiological levels of testosterone (< 50ng/dL) have not been found to significantly increase sexual desire or function in women in most studies. Similarly, there appears to be little to no relationship between total or free testosterone levels within the normal physiological range and sex drive in premenopausal women. Only high doses of testosterone resulting in supraphysiological levels of testosterone (> 50ng/dL) significantly increase sexual desire in women, with levels of testosterone of 80 to 150ng/dL described as "slightly" increasing sex drive. In accordance, men experience sexual dysfunction at testosterone levels of below 300ng/dL, with men that have levels of testosterone of approximately 200ng/dL often experiencing such problems. The high doses of testosterone that are required to increase sex drive in women may have a significant risk of masculinization with long-term therapy, and may be inappropriate. In 2003, the FDA rejected Intrinsa, a 300g/day testosterone patch for the treatment of sexual dysfunction in postmenopausal women, due to limited efficacy (about one additional sexually satisfying event per month), concerns about safety and potential adverse effects with long-term therapy, and concerns about inappropriate off-label use. It appears that in women, rather than testosterone, estradiol may be the most important hormone involved in sexual desire, although data on the clinical use of estradiol to increase sexual desire in women is limited.
There are no testosterone products approved for use in women in the United States and many other countries. There are approved testosterone products for women in Australia and some European countries. Testosterone implants are approved for use in postmenopausal women in the United Kingdom. Testosterone products for men can be used off-label in women in the United States. Alternatively, testosterone products for women are available from compounding pharmacies in the United States, although such products are unregulated and manufacturing quality is not ensured.
Testosterone has been marketed for use by oral, buccal, intranasal, transdermal (patches), topical (gels), intramuscular (injection), and subcutaneous (implant administration. It is provided unmodified and as a testosterone ester such as testosterone cypionate, testosterone enanthate, testosterone propionate, or testosterone undecanoate, which act as prodrugs of testosterone. The most common route of administration for testosterone is by intramuscular injection. However, it has been reported that AndroGel, a transdermal gel formulation of testosterone, has become the most popular form of testosterone in androgen replacement therapy for hypogonadism in the United States.
Testosterone is used as a form of doping among athletes in order to improve performance. Testosterone is classified as an anabolic agent and is on the World Anti-Doping Agency (WADA) List of Prohibited Substances and Methods. Hormone supplements cause the endocrine system to adjust its production and lower the natural production of the hormone, so when supplements are discontinued, natural hormone production is lower than it was originally.
Anabolicandrogenic steroids (AAS), including testosterone and its esters, have also been taken to enhance muscle development, strength, or endurance. They do so directly by increasing the muscles' protein synthesis. As a result, muscle fibers become larger and repair faster than the average person's.
After a series of scandals and publicity in the 1980s (such as Ben Johnson's improved performance at the 1988 Summer Olympics), prohibitions of AAS use were renewed or strengthened by many sports organizations. Testosterone and other AAS were designated a "controlled substance" by the United States Congress in 1990, with the Anabolic Steroid Control Act. Their use is seen as an issue in modern sport, particularly given the lengths to which athletes and professional laboratories go to in trying to conceal such use from sports regulators. Steroid use once again came into the spotlight recently as a result of Canadian professional wrestler Chris Benoit's double murder-suicide in 2007; however, there is no evidence implicating steroid use as a factor in the incident.
Some female athletes may have naturally higher levels of testosterone than others, and may be asked to consent to sex verification and either surgery or drugs to decrease testosterone levels. This has proven contentious, with the Court of Arbitration for Sport suspending the IAAF policy due to insufficient evidence of a link between high androgen levels and improved athletic performance.
A number of methods for detecting testosterone use by athletes have been employed, most based on a urine test. These include the testosterone/epitestosterone ratio (normally less than 6), the testosterone/luteinizing hormone ratio and the carbon-13/carbon-12 ratio (pharmaceutical testosterone contains less carbon-13 than endogenous testosterone). In some testing programs, an individual's own historical results may serve as a reference interval for interpretation of a suspicious finding. Another approach being investigated is the detection of the administered form of testosterone, usually an ester, in hair.
Absolute contraindications of testosterone include prostate cancer, elevated hematocrit (>54%), uncontrolled congestive heart failure, various other cardiovascular diseases, and uncontrolled obstructive sleep apnea. Breast cancer is said by some sources to be an absolute contraindication of testosterone therapy, but androgens including testosterone have also actually been used to treat breast cancer. Relative contraindications of testosterone include elevated prostate-specific antigen (PSA) in men with a high risk of prostate cancer due to ethnicity or family history, severe lower urinary tract symptoms, and elevated hematocrit (>50%).
Adverse effects may also include minor side effects such as oily skin, acne, and seborrhea, as well as loss of scalp hair, which may be prevented or reduced with 5-reductase inhibitors. In women, testosterone can produce hirsutism (excessive facial/body hair growth), deepening of the voice, and other signs of virilization. Exogenous testosterone may cause suppression of spermatogenesis in men, leading to, in some cases, reversible infertility. Gynecomastia and breast tenderness may occur with high dosages of testosterone due to peripheral conversion of testosterone by aromatase into excessive amounts of the estrogen estradiol. Testosterone treatment, particularly in high dosages, can also be associated with mood changes, increased aggression, increased sex drive, spontaneous erections, and nocturnal emissions.
Other side effects include increased hematocrit, which can require venipuncture in order to treat, and exacerbation of sleep apnea.
The FDA stated in 2015 that neither the benefits nor the safety of testosterone have been established for low testosterone levels due to aging. The FDA has required that testosterone pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke. They have also required the label include concerns about abuse and dependence.
Adverse effects of testosterone supplementation may include increased cardiovascular events (including strokes and heart attacks) and deaths based on three peer-reviewed studies involving men taking testosterone replacement. In addition, an increase of 30% in deaths and heart attacks in older men has been reported. Due to an increased incidence of adverse cardiovascular events compared to a placebo group, a Testosterone in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee. On January 31, 2014, reports of strokes, heart attacks, and deaths in men taking FDA-approved testosterone-replacement led the FDA to announce that it would be investigating the issue. Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT). The FDA now requires warnings in the drug labeling of all approved testosterone products regarding deep vein thrombosis and pulmonary embolism.
Up to the year 2010, studies had not shown any effect on the risk of death, prostate cancer or cardiovascular disease; more recent studies, however, do raise concerns. A 2013 study, published in the Journal of the American Medical Association, reported "the use of testosterone therapy was significantly associated with increased risk of adverse outcomes." The study began after a previous, randomized, clinical trial of testosterone therapy in men was stopped prematurely "due to adverse cardiovascular events raising concerns about testosterone therapy safety."
Testosterone in the presence of a slow-growing prostate cancer is assumed to increase its growth rate. However, the association between testosterone supplementation and the development of prostate cancer is unproven. Nevertheless, physicians are cautioned about the cancer risk associated with testosterone supplementation.
It may accelerate pre-existing prostate cancer growth in individuals who have undergone androgen deprivation. It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy.
Ethnic groups have different rates of prostate cancer. Differences in sex hormones, including testosterone, have been suggested as an explanation for these differences. This apparent paradox can be resolved by noting that prostate cancer is very common. In autopsies, 80% of 80-year-old men have prostate cancer.
Testosterone is contraindicated in pregnancy and not recommended during breastfeeding. Androgens like testosterone are teratogens and are known to cause fetal harm, such as producing virilization and ambiguous genitalia.
5-Reductase inhibitors like finasteride and dutasteride can slightly increase circulating levels of testosterone by inhibiting its metabolism. However, these drugs do this via prevention of the conversion of testosterone into its more potent metabolite dihydrotestosterone (DHT), and this results in dramatically reduced circulating levels of DHT (which circulates at much lower relative concentrations). In addition, local levels of DHT in so-called androgenic (5-reductase-expressing) tissues are also markedly reduced, and this can have a strong impact on certain effects of testosterone. For instance, growth of body and facial hair and penile growth induced by testosterone may be inhibited by 5-reductase inhibitors, and this could be considered undesirable in the context of, for instance, puberty induction. On the other hand, 5-reductase inhibitors may prevent or reduce adverse androgenic side effects of testosterone like scalp hair loss, oily skin, acne, and seborrhea. In addition to the prevention of testosterone conversion into DHT, 5-reductase inhibitors also prevent the formation of neurosteroids like 3-androstanediol from testosterone, and this may have neuropsychiatric consequences in some men.
Aromatase inhibitors like anastrozole prevent the conversion of testosterone into estradiol by aromatase. As only a very small fraction of testosterone is converted into estradiol, this does not affect testosterone levels, but it can prevent estrogenic side effects like gynecomastia that can occur when testosterone is administered at relatively high dosages. However, estradiol exerts negative feedback on the hypothalamicpituitarygonadal axis and, for this reason, prevention of its formation can reduce this feedback and disinhibit gonadal production of testosterone, which in turn can increase levels of endogenous testosterone. Testosterone therapy is sometimes combined with an aromatase inhibitor for men with secondary hypogonadism who wish to conceive children with their partners.
Inhibitors and inducers of cytochrome P450 enzymes like CYP3A4 have been associated with little or no effect on circulating testosterone levels.
Antiandrogens like cyproterone acetate, spironolactone, and bicalutamide can block the androgenic and anabolic effects of testosterone. Estrogens can reduce the effects of testosterone by increasing the hepatic production and in turn circulating levels of sex hormone-binding globulin (SHBG), a carrier protein that binds to and occupies androgens like testosterone and DHT, and thereby reducing free concentrations of these androgens.
Testosterone is a high affinity ligand for and agonist of the nuclear androgen receptor (AR). In addition, testosterone binds to and activates membrane androgen receptors (mARs) such as GPRC6A and ZIP9. Testosterone is also potentiated via transformation by 5-reductase into the more potent androgen DHT in so-called androgenic tissues such as the prostate gland, seminal vesicles, skin, and hair follicles. In contrast to the case of testosterone, such potentiation occurs to a reduced extent or not at all with most synthetic AAS (as well as with DHT), and this is primarily responsible for the dissociation of anabolic and androgenic effects with these agents. In addition to DHT, testosterone is converted at a rate of approximately 0.3% into the estrogen estradiol via aromatase. This occurs in many tissues, especially adipose tissue, the liver, and the brain, but primarily in adipose tissue. Testosterone, after conversion into DHT, is also metabolized into 3-androstanediol, a neurosteroid and potent positive allosteric modulator of the GABAA receptor, and 3-androstanediol, a potent and preferential agonist of the ER. These metabolites, along with estradiol, may be involved in a number of the effects of testosterone in the brain, including its antidepressant, anxiolytic, stress-relieving, rewarding, and pro-sexual effects.
The ARs are expressed widely throughout the body, including in the penis, testicles, epididymides, prostate gland, seminal vesicles, fat, skin, bone, bone marrow, muscle, larynx, heart, liver, kidneys, pituitary gland, hypothalamus, and elsewhere throughout the brain. Through activation of the ARs (as well as the mARs), testosterone has many effects, including the following:[additional citation(s) needed]
Testosterone is not active orally except in extremely high dosages due to poor absorption and extensive first-pass metabolism. In addition, steroidal androgens including testosterone are hepatotoxic and there is a potential for liver injury with high dosages of oral testosterone due to the production of supraphysiological local concentrations of drug in the liver. Instead of oral ingestion, testosterone is administered parenterally in the form of topical gels and creams, transdermal patches, buccal tablets, and subdermal implants. In addition, it is administered via depot intramuscular injection in the form of long-acting ester prodrugs such as testosterone cypionate, testosterone enanthate, and testosterone propionate, as well as the particularly long-lasting testosterone undecanoate. Testosterone buciclate is an even longer-acting testosterone ester that has been developed, but has yet to be approved for medical use.
Although testosterone itself is not used orally, testosterone undecanoate is approved and used orally. Due to the unique chemical properties afforded by its very long ester chain, testosterone undecanoate partially bypasses first-pass liver metabolism via absorption from the gastrointestinal tract directly into the lymphatic system and then into circulation. Of oral testosterone undecanoate that reaches circulation, 90 to 100% is transported lymphatically. This ester is not hepatotoxic at the dosages used. However, oral testosterone undecanoate has variable pharmacokinetics and must be taken two to four times a day with food. In addition to testosterone undecanoate, the combination of testosterone with a 5-reductase inhibitor like dutasteride can render testosterone orally active when it is given in the form of oil-filled capsules. This is via reduction of the first-pass hepatic metabolism of testosterone.
The oral bioavailability of testosterone is very low and virtually negligible. The bioavailability of oral testosterone undecanoate is 3 to 7%. Topical testosterone gels have a bioavailability of 10% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs. The bioavailability of testosterone via implant is virtually 100%, while the bioavailability of drugs that are administered intramuscularly is generally almost 95%.
In circulation, 97.0 to 99.5% of testosterone is bound to plasma proteins, with 0.5 to 3.0% unbound. It is tightly bound to SHBG and weakly to albumin. Of circulating testosterone, 30 to 44% is bound to SHBG while 54 to 68% is bound to albumin. Testosterone that is unbound is referred to as free testosterone and testosterone that is bound to albumin is referred to as bioavailable testosterone. Unlike testosterone that is bound to SHBG, bioavailable testosterone is bound to plasma proteins weakly enough such that, similarly to free testosterone, it may be biologically active, at least to some extent. When referenced collectively (i.e., free, bioavailable, and SHBG-bound), circulating testosterone is referred to as total testosterone.
Testosterone is metabolized primarily in the liver mainly (90%) by reduction via 5- and 5-reductase and conjugation via glucuronidation and sulfation. The major urinary metabolites of testosterone are androsterone glucuronide and etiocholanolone glucuronide.
The elimination half-life of testosterone varies depending on the route of administration and formulation and on whether or not it is esterified. Oral testosterone undecanoate (in oil capsules) has a terminal half-life of 1.6 hours. Because of its very short terminal half-life, oral testosterone undecanoate is taken two to four times per day. In contrast to oral testosterone, other forms of testosterone including topical gels and solutions, transdermal patches, and buccal tablets have an extended-release effect and can be administered less frequently, at intervals, depending on the route/formulation, of once a day, twice a day, or once every other day.
Whereas the terminal half-life of unesterified testosterone administered via intramuscular injection is very short at only around 10 minutes, the terminal half-lives of intramuscular testosterone esters are far longer. Administered in the form of oil solutions, the terminal half-lives are 0.8 days for testosterone propionate, 4.5 days for testosterone enanthate, 20.9 days (in tea seed oil) and 33.9 days (in caster oil) for testosterone undecanoate, and 29.5 days for testosterone buciclate. Although exact values are not available for intramuscular testosterone cypionate, its pharmacokinetics are said to be the same as those of testosterone enanthate, with "extremely comparable" patterns of testosterone release. Due to their varying and different terminal half-lives, the different intramuscular testosterone esters are administered with differing frequencies. Testosterone propionate is injected two to three times per week, testosterone enanthate and testosterone cypionate are injected once every two to four weeks, and testosterone undecanoate and testosterone buciclate are injected once every 10 to 14 weeks. Due to its relatively short duration, testosterone propionate is now relatively little used and testosterone undecanoate is the preferred testosterone ester for intramuscular use. Testosterone undecanoate and testosterone buciclate can be injected intramuscularly as little as four times per year.
The absorption half-life of subdermal testosterone implants is 2.5 months. The replacement interval is once every four to five months.
Testosterone and its metabolites are eliminated in the urine. It is excreted mainly as androsterone glucuronide and etiocholanolone glucuronide. It is also excreted to a small extent as other conjugates such as testosterone glucuronide (1%), testosterone sulfate (0.03%), and androstanediol glucuronides. Only a very small amount of testosterone (less than 0.01%) is found unchanged in the urine.
Testosterone is a naturally occurring androstane steroid and is also known by the chemical name androst-4-en-17-ol-3-one. It has a double bond between the C4 and C5 positions (making it an androstene), a ketone group at the C3 position, and a hydroxyl (alcohol) group at the C17 position.
Testosterone esters are substituted at the C17 position with a lipophilic fatty acid ester moiety of varying chain length. Major testosterone esters include testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone undecanoate. A C17 ether prodrug of testosterone, cloxotestosterone acetate, has also been marketed, although it is little known and is used very rarely or no longer. Another C17 ether prodrug of testosterone, silandrone, also exists but was never marketed, and is notable in that it is orally active. In addition to ester and ether prodrugs, androgen prohormones or precursors of testosterone, such as dehydroepiandrosterone (DHEA), androstenediol, and androstenedione, exist as well, and convert into testosterone to variable extents upon oral ingestion. Unlike testosterone ester and ether prodrugs however, these prohormones are only weakly androgenic/anabolic.
All synthetic AAS are derivatives of testosterone. Prominent examples include nandrolone (19-nortestosterone), metandienone (17-methyl-1-testosterone), and stanozolol (a 17-alkylated derivative of DHT). Unlike testosterone, AAS that are 17-alkylated, like metandienone and stanozolol, are orally active. This is due to steric hindrance of C17-position metabolism during the first-pass through the liver. In contrast, most AAS that are not 17-alkylated, like nandrolone, are not active orally, and must instead be administered via intramuscular injection. This is almost always in ester form; for instance, in the case of nandrolone, as nandrolone decanoate or nandrolone phenylpropionate.
Testosterone was first isolated and synthesized in 1935. Shortly thereafter, in 1937, testosterone first became commercially available as a pharmaceutical drug in the form of pellets and then in ester form for intramuscular injection as the relatively short-acting testosterone propionate. Methyltestosterone, one of the first synthetic AAS and orally active androgens, was introduced in 1935, but was associated with hepatotoxicity and eventually became largely medically obsolete. In the mid-1950s, the longer-acting testosterone esters testosterone enanthate and testosterone cypionate were introduced. They largely superseded testosterone propionate and became the major testosterone esters used medically for over half a century. In the 1970s, testosterone undecanoate was introduced for oral use in Europe, although intramuscular testosterone undecanoate had already been in use in China for several years. Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later (in the early to mid 2000s and 2014, respectively).
In the US in the 2000s, companies and figures in the popular media have heavily marketed notions of "andropause" as something parallel to menopause; these notions have been rejected by the medical community. Additionally, advertising from drug companies selling testosterone and human growth hormone, as well as dietary supplement companies selling all kinds of "boosters" for aging men, have emphasized the "need" of middle-aged or ageing men for testosterone. There is a medical condition called late-onset hypogonadism; according to Thomas Perls and David J. Handelsman, writing in a 2015 editorial in the Journal of the American Geriatrics Society, it appears that this condition is overdiagnosed and overtreated. Perls and Handelsman note that in the US, "sales of testosterone increased from $324 million in 2002 to $2 billion in 2012, and the number of testosterone doses prescribed climbed from 100 million in 2007 to half a billion in 2012, not including the additional contributions from compounding pharmacies, Internet, and direct-to-patient clinic sales."
Testosterone is the generic name of testosterone in English and Italian and the INN, USAN, USP, BAN, and DCIT of the drug, while testostrone is its French name and the DCF. It is also referred to in Latin as testosteronum, in Spanish and Portuguese as testosterona, and in German, Dutch, and Russian and other Slavic languages as testosteron. The Cyrillic script of testosterone is .
Testosterone is marketed under a large number of brand names throughout the world. Major brand names of testosterone and/or its esters include Andriol, Androderm, AndroGel, Axiron, Delatestryl, Depo-Testosterone, Intrinsa, Nebido, Omnadren, Primoteston, Sustanon, Testim, TestoGel, TestoPatch, Testoviron, and Tostran.
As of November2016[update], unmodified (non-esterified) testosterone is available in the United States in the following formulations:
And the following ester prodrugs of testosterone are available in the United States in oil solutions for intramuscular injection:
Unmodified testosterone was also formerly available for intramuscular injection but was discontinued.
Testosterone cypionate and testosterone enanthate were formerly available in combination with estradiol cypionate and estradiol valerate, respectively, under the brand names Depo-Testadiol and Ditate-DS, respectively, as oil solutions for intramuscular injection, but these formulations have been discontinued.
Unlike in Europe, Canada, and much of the rest of the world, oral testosterone undecanoate is not available in the United States.
As of November2016[update], testosterone is available in Canada in the form of topical gels (AndroGel, Testim), topical solutions (Axiron), transdermal patches (Androderm), and intranasal gels (Natesto). Testosterone cypionate (Depo-Testosterone, Testosterone Cypionate (generic)), testosterone enanthate (Delatestryl, PMS-Testosterone Enanthate), and testosterone propionate (Testosterone Propionate (generic)) are available as oil solutions for intramuscular injection and testosterone undecanoate (Andriol, PMS-Testosterone, Taro-Testosterone) is available in the form of oral capsules. Testosterone buccal tablets and pellet implants do not appear to be available in Canada.
Testosterone and/or its esters are widely available in countries throughout the world in a variety of formulations.
Testosterone and its esters, along with other AAS, are prescription-only controlled substances in many countries throughout the world. In the United States, they are Schedule III drugs under the Controlled Substances Act, in Canada, they are Schedule IV drugs under the Controlled Drugs and Substances Act, and in the United Kingdom, they are Class C drugs under the Misuse of Drugs Act.
As of 2014, a number of lawsuits are underway against manufacturers of testosterone, alleging a significantly increased rate of stroke and heart attack in elderly men who use testosterone supplementation.
There are many known cases of doping in sports with testosterone and its esters by professional athletes.
Testosterone has been used to treat depression in men who are of middle age with low testosterone. However, a 2014 review showed no benefit on the mood of the men with normal levels of testosterone or on the mood of the older men with low testosterone. Conversely, a 2009 review found that testosterone had an antidepressant effect in men with depression, especially those with hypogonadism, HIV/AIDS, and in the elderly.
Testosterone replacement can significantly improve exercise capacity, muscle strength and reduce QT intervals in men with chronic heart failure (CHF). Over the 3 to 6-month course of the studies reviewed, testosterone therapy appeared safe and generally effective, and (ruling out prostate cancer) the authors found no justification to absolutely restrict its use in men with CHF. A similar 2012 review also found increased exercise capacity and reasoned the benefits generlizable to women. However, both reviews advocate larger, longer term, randomized controlled trials.
Testosterone, as esters such as testosterone undecanoate or testosterone buciclate, has been studied and promoted as a male contraceptive analogous to estrogen-based contraceptives in women. Otherwise considered an adverse effect of testosterone, reduced spermatogenesis can be further suppressed with the addition of a progestin such as norethisterone enanthate or levonorgestrel butanoate, improving the contraceptive effect.
Testosterone is under development in a low-dose intranasal formulation for the treatment of anorgasmia in women.
A study found that of 76 pre- and postmenopausal women with hair thinning, 63% experienced hair regrowth when treated with subcutaneous testosterone implants that resulted in average testosterone levels of over 300ng/dL for 12months. No woman reported hair loss or thinning during testosterone treatment.
Testosterone therapy may improve the management of type 2 diabetes. Low testosterone has been associated with the development of Alzheimer's disease.
Topical androgens like testosterone have been used and studied in the treatment of cellulite in women.
Read this article:
- Testosterone Therapy - Royal Men's Medical Center - December 10th, 2019
- BioTE Medical Founder and Chairman Warns of Potential Serious Impact on Women's Health from Recent Position Statement on Women's Testosterone Therapy... - December 10th, 2019
- Testosterone Replacement Therapy Market Expected to Deliver Dynamic Progression until 2028| AbbVie, Endo International, Eli lilly - Breaking News... - December 10th, 2019
- Testosterone Replacement Therapy Market Top Players (Endo International, AbbVie, Eli lilly, Pfizer, Actavis, Bayer, Novartis, Teva, Mylan,... - December 10th, 2019
- People Are Poisoning Themselves With Essential Oils. Please Don't - IFLScience - December 10th, 2019
- What are the signs of low testosterone levels in men? - Times of India - December 8th, 2019
- Relugolix Induces Sustained Testosterone Reduction in Advanced PC, Phase 3 Trial Results Show - Prostate Cancer News Today - December 8th, 2019
- Surgeons Transplant a Testicle From One Brother to His Twin - The New York Times - December 8th, 2019
- Two teams 'full of testosterone': Ducks ready for grudge rematch with Capitals - The Athletic - December 8th, 2019
- What are the rules for trans athletes in football? - Goal.com - December 8th, 2019
- Testosterone: What It Can And Can't Do, Signs You're Low, And How To Increase It - Men's Health - December 8th, 2019
- Global Testosterone Replacement Therapy Market Insights, Growth Analysis, Forecasts to 2025: Endo International, AbbVie, Eli lilly, Pfizer, Actavis ,... - December 8th, 2019
- Prostate Cancer Development May Be Linked to High Blood Levels of 2 Hormones, Study Says - Prostate Cancer News Today - December 8th, 2019
- Transitioning: a threat to our children - Spiked - December 8th, 2019
- Testosterone Replacement Therapy Market to See Admirable Grrowth by 2024 According to a New Research Report - Kentucky Reports - December 3rd, 2019
- Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational - Financial Post - December 3rd, 2019
- The Wolf of Wall Street Immersive Experience, review: an overlong scenario with the barely contained testosterone of a stag party - inews - December 3rd, 2019
- Daughters of women with PCOS face five times greater risk - The Guardian - December 3rd, 2019
- Where Have All the Alphas Gone? | Columns - PJ Media - December 3rd, 2019
- The Pill Can Make You Less Attracted to Jerks, and Other Surprising Facts About Birth Control - Yahoo Lifestyle - December 3rd, 2019
- Testosterone Replacement Therapy Market To Witness Robust Expansion Throughout The Forecast Period 2019 2025 - Statsflash - December 3rd, 2019
- What supplements in the Exchange are worth your money? Part 3 - We Are The Mighty - December 3rd, 2019
- Should You Worry About Swollen Testicles? - University of Utah Health Care - November 22nd, 2019
- Symptoms of Low Testosterone in Men - FortuneHerald - November 22nd, 2019
- Testosterone Replacement Therapy Market To Witness Huge Growth in 2024 - Downey Magazine - November 22nd, 2019
- At-home testing kits could help Maryland residents engage in their health - WBAL TV Baltimore - November 22nd, 2019
- 8 Awful Things That Happen to You After You Turn 30 (And What You Can Do to Stop Them) - Mandatory - November 22nd, 2019
- Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants - The Herald Journal - November 22nd, 2019
- Why men who compete as female will always have an unfair advantage over real women - Lifesite - November 22nd, 2019
- Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants - The Herald Journal - November 22nd, 2019
- Crush Your Fitness Goals with This Fat Burner and Testosterone Booster - Men's Journal - November 15th, 2019
- Acerus Reports Third Quarter and Year-to-Date Fiscal 2019 Financial Results - Business Wire - November 15th, 2019
- Hormone therapy offered by Student Health Service - UWEC Spectator - November 15th, 2019
- Same-sex relationship to unnatural testosterone, why Dutee Chand is the only Indian to feature on 'TIME 100 Next' - Free Press Journal - November 15th, 2019
- Testosterone therapy prescription linked to increased VTE risk in JAMA study - Specialty Medical Dialogues - November 15th, 2019
- New book refutes 'boys will be boys' - Futurity: Research News - November 15th, 2019
- A Myth Of Masculinity: The Truth About Testosterone - KGOU - November 12th, 2019
- What is Testosterone and Why is it Important? - News Anyway - November 12th, 2019
- Value and Size Of Testosterone Replacement Therapy Market From 2019 To 2024: Detailed Research Report - The Denton Chronicle - November 12th, 2019
- Testosterone Replacement Therapy Industry: Time to Invest in emerging Markets | Endo International, Pfizer, Novartis - News Description - November 12th, 2019
- Global Testosterone Replacement Therapy Market Size And Share 2019: With Top Manufacturers, Applications, Key Regions, Growth Opportunities Forecast... - November 12th, 2019
- Testosterone Replacement Therapy: Controversy and Trends - Medscape - November 11th, 2019
- Lawsuit claims contract breached over transgender testosterone therapy - The San Diego Union-Tribune - November 11th, 2019
- Traces of testosterone: US womens tennis star provisionally suspended for doping violation - RT - November 11th, 2019
- LANE ONE: IAAF taking the lead in transgender regulation, working with other IFs on testosterone levels - The Sports Examiner - November 11th, 2019
- Nike will look into runner Mary Cain's allegations of abuse - Minneapolis Star Tribune - November 11th, 2019
- Everything you need to know about steroids - RTE.ie - November 11th, 2019
- The double standard of feminism - University Star - November 11th, 2019
- Hearing into Team Sky doctor's lies in danger of being sent down blind alleys while the dirty secrets of Dave Brailsford's project stay uncovered -... - November 11th, 2019
- Brazil Nuts and Testosterone: Is There a Link? - Healthline - October 30th, 2019
- Side Effects of Hormone Therapy - Prostate Cancer Foundation - October 30th, 2019
- Is testosterone really the answer to my post-menopausal sexual problems? - The Guardian - October 30th, 2019
- Women are more likely to be diagnosed with depression. MSU study may help explain why. - Michigan Radio - October 30th, 2019
- Former Team Sky doctor Richard Freeman to admit to a lot of lies - Irish Times - October 30th, 2019
- Cory Booker Condemns 'Lock Him Up' Chant Against The President - The Daily Wire - October 30th, 2019
- Why has the field of male contraception not seen any progress? - Business Insider India - October 30th, 2019
- The link between anabolic steroids and gynecomastia in men - MENAFN.COM - October 30th, 2019
- Optimizing Diagnosis and Management of PCOS in Pediatric Patients - Endocrinology Advisor - October 22nd, 2019
- How To Deal When You Don't Want To *Do It* As Much As Your SO - Women's Health - October 22nd, 2019
- Testosterone Replacement Therapy Market Growing Demand, Analysis by Key Players-Bayer, Novartis - The Market Journal - October 22nd, 2019
- Krygen XL has now become the best priced and best reviewed male enhancement supplement in the UK - I'm Herald - October 22nd, 2019
- Testosterone Booster Market Distinguished Technology Development with Major Production Goals Analysis by 2026 - Connecting Investor - October 22nd, 2019
- Katrina Karkazis on the Science of Masculinity - GQ - October 20th, 2019
- Sarah Connor Tested Testosterone To Make Her Role In TERMINATOR - Somag News - October 20th, 2019
- Can't Grow a Full Beard? There's an Explanation for That - Health Essentials from Cleveland Clinic - October 20th, 2019
- Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. - UroToday - October 20th, 2019
- SIU 2019: Timing of ADT in the Era of STAMPEDE and LATITUDE - UroToday - October 20th, 2019
- A clinic treated a fatigued 41-year-old with testosterone. A month later he had a stroke. - CBS News - October 17th, 2019
- Harvard says masculinity and testosterone are not 'connected' - The College Fix - October 17th, 2019
- Associations Between Sex Hormones and Asthma in Adults - Pulmonology Advisor - October 17th, 2019
- Science! Harvard Disputes the Idea That Testosterone and Masculinity are Connected - legal Insurrection - October 17th, 2019
- Global Testosterone Replacement Therapy Market Industry: A Latest Research Report to Share Market Insights and Dynamics - Healthcare News - October 17th, 2019
- Testosterone Replacement Therapy Market: An Insight on the Important Factors and Trends Influencing the Market - Online News Guru - October 17th, 2019
- Nike closing Oregon Project in wake of Salazar doping ban - CTV News - October 17th, 2019
- Cardiometabolic Effects of Gender-Affirming Hormone Therapy in Transgender Youth - The Cardiology Advisor - October 14th, 2019
- Nike to Shut Down Salazars Oregon Project - The New York Times - October 12th, 2019
- Global consensus statement on using testosterone therapy for women - Contemporary Obgyn - October 12th, 2019
- Nike Oregon Project will 'wind down' after Alberto Salazar's doping violation ban - KGW.com - October 12th, 2019
- How to know if you have low testosterone. - KNWA - September 27th, 2019
- Britain's Sharp eliminated in opening 800 metres heat - Euronews - September 27th, 2019